Published in Nat Immunol on December 09, 2002
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol (2009) 2.34
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol (2011) 1.46
Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc Natl Acad Sci U S A (2005) 1.46
How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J (2007) 1.44
Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit (2008) 1.34
Dual, HLA-B27 subtype-dependent conformation of a self-peptide. J Exp Med (2004) 1.31
Protein dynamics and the immunological evolution of molecular recognition. Proc Natl Acad Sci U S A (2004) 1.24
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 1.21
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol (2009) 1.20
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
Structural basis of specificity and cross-reactivity in T cell receptors specific for cytochrome c-I-E(k). J Immunol (2011) 1.15
Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation. J Immunol (2008) 1.12
Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A (2012) 1.01
Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods (2008) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther (2012) 0.99
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Eng Des Sel (2010) 0.98
Reconciling views on T cell receptor germline bias for MHC. Trends Immunol (2012) 0.98
Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function. Immunol Rev (2012) 0.98
The effects of thymic selection on the range of T cell cross-reactivity. Eur J Immunol (2005) 0.94
Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors. Biochemistry (2008) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
Revisiting thymic positive selection and the mature T cell repertoire for antigen. Immunity (2014) 0.92
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther (2011) 0.91
Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 0.91
Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. AIDS (2010) 0.91
Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity. J Immunol (2009) 0.91
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol (2008) 0.90
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother (2012) 0.88
Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front Immunol (2013) 0.88
T-cell promiscuity in autoimmune diabetes. Diabetes (2008) 0.88
Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. Clin Exp Immunol (2005) 0.88
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides. J Biol Chem (2009) 0.87
High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics. Mol Immunol (2010) 0.87
HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood (2011) 0.87
Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs. J Immunol (2011) 0.86
The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol (2010) 0.86
Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther (2012) 0.86
Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J Immunol Methods (2013) 0.85
Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity. Mol Immunol (2006) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Identification of multiple public TCR repertoires in chronic beryllium disease. J Immunol (2014) 0.84
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med (2005) 0.84
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol (2013) 0.83
Rational design of T cell receptors with enhanced sensitivity for antigen. PLoS One (2011) 0.83
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia (2015) 0.82
Glassy dynamics in the adaptive immune response prevents autoimmune disease. Phys Rev Lett (2005) 0.82
Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 0.82
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 0.82
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Changing the peptide specificity of a human T-cell receptor by directed evolution. Nat Commun (2014) 0.80
Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response. Front Immunol (2015) 0.80
Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8. J Immunol (2011) 0.80
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol Sci (2015) 0.79
Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. Biotechnol Prog (2012) 0.78
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) (2010) 0.78
Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77
Age-related accumulation of T cells with markers of relatively stronger autoreactivity leads to functional erosion of T cells. BMC Immunol (2012) 0.77
Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep (2016) 0.77
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells. Sci Rep (2016) 0.77
Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex. J Biol Chem (2016) 0.76
New approaches for the immunotherapy of acute myeloid leukemia. Discov Med (2015) 0.75
Recent advances in T-cell engineering for use in immunotherapy. F1000Res (2016) 0.75
A unifying mathematical framework for experimental TCR-pMHC kinetic constants. Sci Rep (2017) 0.75
Cumulative autoimmunity: T cell clones recognizing several self-epitopes exhibit enhanced pathogenicity. Front Immunol (2011) 0.75
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
How a single T cell receptor recognizes both self and foreign MHC. Cell (2007) 3.20
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity (2003) 3.04
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
Structural basis of affinity maturation and intramolecular cooperativity in a protein-protein interaction. Structure (2005) 1.70
Expression profiling using a hexamer-based universal microarray. Nat Biotechnol (2004) 1.69
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood (2013) 1.63
Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat Immunol (2003) 1.54
Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med (2007) 1.52
Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis (2009) 1.47
Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc Natl Acad Sci U S A (2005) 1.46
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
Long-range cooperative binding effects in a T cell receptor variable domain. Proc Natl Acad Sci U S A (2006) 1.26
Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J Mol Biol (2005) 1.25
Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition. Immunity (2009) 1.22
High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol (2004) 1.21
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol (2009) 1.20
A model T-cell receptor system for studying memory T-cell development. Microbes Infect (2003) 1.19
Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis (2010) 1.18
Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation. J Immunol (2008) 1.12
Engineering and characterization of a stabilized alpha1/alpha2 module of the class I major histocompatibility complex product Ld. J Biol Chem (2006) 1.12
Rapid method for measuring ScFv thermal stability by yeast surface display. Biotechnol Prog (2003) 1.09
The study of high-affinity TCRs reveals duality in T cell recognition of antigen: specificity and degeneracy. J Immunol (2006) 1.08
Display, engineering, and applications of antigen-specific T cell receptors. Biomol Eng (2007) 1.08
Solution mapping of T cell receptor docking footprints on peptide-MHC. Proc Natl Acad Sci U S A (2007) 1.06
T cell receptors: affinities, cross-reactivities, and a conformer model. Mol Immunol (2004) 1.03
Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J (2007) 1.03
Disulfide bond engineering to trap peptides in the MHC class I binding groove. J Immunol (2007) 1.02
Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A (2012) 1.01
Crystal structure of a complete ternary complex of TCR, superantigen and peptide-MHC. Nat Struct Mol Biol (2007) 1.00
Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods (2008) 1.00
Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng (2003) 0.99
Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family. Immunity (2007) 0.99
Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther (2012) 0.99
Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol (2009) 0.99
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Eng Des Sel (2010) 0.98
Dissecting cooperative and additive binding energetics in the affinity maturation pathway of a protein-protein interface. J Biol Chem (2003) 0.97
Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother (2011) 0.95
TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J Immunol (2014) 0.94
Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors. Biochemistry (2008) 0.94
Novel platform for the detection of Staphylococcus aureus enterotoxin B in foods. Appl Environ Microbiol (2012) 0.92
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology (2012) 0.91
Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells. Endocrinology (2005) 0.91
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol (2008) 0.90
A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes. Clin Vaccine Immunol (2010) 0.90
Neuronal localization of indoleamine 2,3-dioxygenase in mice. Neurosci Lett (2005) 0.89
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother (2012) 0.88
Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Infect Dis (2008) 0.87
High-affinity T cell receptor differentiates cognate peptide-MHC and altered peptide ligands with distinct kinetics and thermodynamics. Mol Immunol (2010) 0.87
Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides. J Biol Chem (2009) 0.87
Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. J Immunol (2009) 0.87
Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs. J Immunol (2011) 0.86
Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev (2004) 0.86
Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity. Mol Immunol (2006) 0.85
Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PLoS One (2012) 0.85
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Costimulatory strength influences the differential effects of transforming growth factor beta1 for the generation of CD8+ regulatory T cells. Mol Immunol (2008) 0.83
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. J Mol Biol (2013) 0.83
A yeast display system for engineering functional peptide-MHC complexes. J Immunol Methods (2003) 0.83
Molecular basis of a million-fold affinity maturation process in a protein-protein interaction. J Mol Biol (2011) 0.83
Allogeneic and syngeneic class I MHC complexes drive the association of CD8 and TCR on 2C T cells. Mol Immunol (2003) 0.83
Biosensor detection systems: engineering stable, high-affinity bioreceptors by yeast surface display. Methods Mol Biol (2009) 0.82
Assessing energetic contributions to binding from a disordered region in a protein-protein interaction . Biochemistry (2010) 0.82
Cutting edge: inhibitory effects of CD4 and CD8 on T cell activation induced by high-affinity noncognate ligands. J Immunol (2009) 0.82
Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors. Cancer Immunol Immunother (2008) 0.81
T cell receptor engineering. Methods Enzymol (2012) 0.81
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81
Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8. J Immunol (2011) 0.80
Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. Biotechnol Prog (2012) 0.78
Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo. Autoimmunity (2011) 0.78
Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism. J Immunother (2007) 0.77
The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system. J Biol Chem (2013) 0.77
Subtle changes in TCRα CDR1 profoundly increase the sensitivity of CD4 T cells. Mol Immunol (2012) 0.77
T Cell Receptor Engineering and Analysis Using the Yeast Display Platform. Methods Mol Biol (2015) 0.77
T cell receptor CDRs: starring versus supporting roles. Nat Immunol (2005) 0.76
Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes. PLoS One (2012) 0.75
T cells use rafts for survival. Immunity (2010) 0.75
A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjug Chem (2004) 0.75
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell (2016) 0.75
Directed evolution of T-cell receptors for binding superantigens. Methods Mol Biol (2003) 0.75
Imaging membrane intercalating near infrared dyes to track multiple cell populations. J Immunol Methods (2009) 0.75
Analysis of superantigen binding to soluble T-cell receptors. Methods Mol Biol (2003) 0.75